ArticleFrontiers in cellular and infection microbiology2025
Age-specific kinetics of neutralizing antibodies and infection enhancement among ≤1 year-old Indian infants.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Infants born to dengue-immune mothers acquire maternal antibodies to dengue. Maternal antibodies decline over time, making infants susceptible to primary dengue infections. Another important concern is the role of maternal antibodies in causing antibody-dependent enhancement (ADE) during primary infections. In this study, we aimed to investigate the kinetics of dengue virus (DENV)-neutralizing antibodies and infection-enhancing activity in Indian infants. Methods: Healthy infants at birth (cord blood), and at 3, 6, 9, and 12 months of age (n=32/group) were included in this cross-sectional study. Serum samples were tested for neutralizing antibodies using the foci-reduction neutralization test and enhancing antibodies using the ADE assay against DENV1-4 serotypes. Results: Neutralizing antibody positivity declined with the increasing age of the infants. Undetectable levels of neutralizing antibodies to DENV1-4 serotypes were reported in 84% of infants by 9 months. Significantly lower neutralizing antibody titers were also reported in 9-month-old infants compared to that in 6-month-old infants and infants at birth. Comparable levels of enhancement of DENV1-4 infection at a particular dilution to at least one serotype were noted in infants at 3 and 6 months of age. Fold enhancement of DENV1-4 infection was found to be highest in 6-month-old infants at a dilution of 1:20. In summary, our data suggests that DENV infection-enhancing activity aligns with the decline of neutralizing antibodies. Conclusion: Our study indicates that maternally acquired neutralizing antibodies could be protective until 6 months of age and capable of facilitating ADE on exposure to dengue infections in later months of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.